175137-46-9 Usage
Description
5-CYCLOPROPYL-2H-PYRAZOL-3-YLAMINE is a chemical compound that serves as a crucial raw material and intermediate in various industries, including organic synthesis, pharmaceuticals, agrochemicals, and dyestuff. Its unique molecular structure allows it to be utilized in the development of new compounds and products across these sectors.
Uses
Used in Organic Synthesis:
5-CYCLOPROPYL-2H-PYRAZOL-3-YLAMINE is used as a key intermediate for the synthesis of various organic compounds. Its presence in the molecular structure can enhance the properties of the final products, making it a valuable component in the development of new organic materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-CYCLOPROPYL-2H-PYRAZOL-3-YLAMINE is used as a vital building block in the development of new drugs. Its unique chemical properties allow it to be incorporated into the molecular structure of potential therapeutic agents, contributing to their efficacy and safety.
Used in Agrochemicals:
5-CYCLOPROPYL-2H-PYRAZOL-3-YLAMINE is used as an essential raw material in the agrochemical industry. It plays a significant role in the development of new pesticides, herbicides, and other agricultural chemicals, helping to improve their effectiveness and reduce their environmental impact.
Used in Dyestuff Industry:
In the dyestuff industry, 5-CYCLOPROPYL-2H-PYRAZOL-3-YLAMINE is used as a crucial intermediate for the synthesis of various dyes and pigments. Its incorporation into the molecular structure of these colorants can enhance their colorfastness, brightness, and stability, making it an indispensable component in the production of high-quality dyes and pigments.
Physical Form
Liquid
Check Digit Verification of cas no
The CAS Registry Mumber 175137-46-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,1,3 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 175137-46:
(8*1)+(7*7)+(6*5)+(5*1)+(4*3)+(3*7)+(2*4)+(1*6)=139
139 % 10 = 9
So 175137-46-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3/c7-6-3-5(8-9-6)4-1-2-4/h3-4H,1-2H2,(H3,7,8,9)
175137-46-9Relevant articles and documents
2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof
-
Paragraph 0197; 0588; 0589-0590, (2020/03/03)
The invention relates to 2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof. Specifically, the invention discloses the compounds represented by a formula (I) shown in the specification, enantiomers, diastereomers, racemates or a mixture of the compounds, or a pharmaceutically acceptable salt, hydrate and solvate of the compounds, a preparation method of the above materials, and applications of the above materials in preparation of an ASK1 small molecule inhibitor, or medicines for preventing and/or treating diseases related to ASK1, especially liver diseases, lung diseases, cardiovascular diseases, kidney diseases and metabolic diseases.
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy
Rana, Sandeep,Sonawane, Yogesh A.,Taylor, Margaret A.,Kizhake, Smitha,Zahid, Muhammad,Natarajan, Amarnath
supporting information, p. 3736 - 3740 (2018/10/24)
We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.
BENZENE SULFONAMIDES AS CCR9 INHIBITORS
-
Page/Page column 74, (2015/07/15)
The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).